Geffen Aud/Fr M17

Nicolas Madigan, M.B., B.Ch., BAO, Ph.D.
"Genome Editing Technologies and Their Potential to Treat Neurologic Disease"

Learning objectives:
Recognize the mechanisms of genome editing using CRISPR/Cas9 and TALEN technologies
Recognize how rapidly these technologies are advancing to influence diverse biologic applications
Identify how CRISPR/Cas9 and TALEN systems are being used to develop new therapies for neurologic disease
Identify the translational challenges of reagent delivery, targeting specificity, and repair pathway control
Identify ethical implications of genome editing technologies

The presenter (nor spouse/partner) does not have a relevant financial relationship to disclose and does not intend to discuss an off-label/investigative use of a commercial product/device.